News >

Frontline Osimertinib Approaches European Approval for NSCLC

Jason M. Broderick @jasoncology
Published: Friday, Apr 27, 2018

Sean Bohen, MD, PhD

Sean Bohen, MD, PhD
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of osimertinib (Tagrisso) as a first-line treatment for patients with non–small cell lung cancer (NSCLC) whose tumors harbor activating EGFR mutations, according to AstraZeneca, the manufacturer of the third-generation, irreversible EGFR TKI. 

Overall, 33.7% of patients experienced a grade ≥3 AE in the osimertinib group compared with 44.8% for erlotinib and gefitinib. Patients in the osimertinib group were less likely to discontinue treatment because of AEs (13.3% vs 18.1%).
Ramalingam S, Reungwetwattana T, Chewaskulyong B, et al. Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA. Presented at: 2017 ESMO Congress; Madrid, Spain; September 9-12, 2017. Abstract LBA2_PR.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Publication Bottom Border
Border Publication
x